Auteur : Cohen, Jeffrey A. (Jeffrey Alan) / Rudick, Richard A.

Édition : 4th edition

Maison d'édition : Cambridge University Press

Date de publication : 2011

Collation : xvii, [8] p. de pl., 752 p. : ill.

ISBN : 9780521766272

Langue : Anglais

Table des matières : 1. Aspects of multiple sclerosis that relate to experimental therapeutics -- 2. The pathology of multiple sclerosis -- 3. The immunology of multiple sclerosis -- 4. The genetics of multiple sclerosis -- 5. The epidemiology of multiple sclerosis -- 6. Measures of neurological impairment and disability in multiples sclerosis -- 7. Assessment of neuropsychological function in multiple sclerosis -- 8. Health-related quality of life assessment in multiple sclerosis -- 9. Measures of acute and chronic lesions visualized by conventional magnetic -- 10. Measures of magnetization transfer -- 11. Measurement of CNS atrophy -- 12. Axonal pathology in patients with multiple sclerosis : evidence from in vivo proton magnetic resonance spectroscopy -- 13, Imaging of gray matter lesions in multiple sclerosis -- 14. Functional imaging in multiple sclerosis -- 15. Diffusion imaging in multiple sclerosis -- 16. The use of MRI in multiple sclerosis clinical trials -- 17. Optical coherence tomography to monitor axonal and neuronal integrity in multiple sclerosis -- 18. The process of drug development and approval in the United States, the Europea Union and Asia -- 19. Selection, interpretation and development of end-points in multiple sclerosis clinical trials -- 20. The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis -- 21. The growing need for alternative clinical trial designs for multiple sclerosis -- 22. Ethical considerations in multiple sclerosis clinical trials -- 23. Pharmacogenomics and related discovery-driven approaches in multiple sclerosis -- 24. Neutralizing antibodies directed against biologic agents to treat multiple sclerosis -- 25. Interferon beta to treat multiple sclerosis -- 26. Glatiramer acetate to treat multiple sclerosis -- 27. Natalizumab to treat mujltiple sclerosis -- 28. Mitoxantrone to treat multiple sclerosis -- 29. Cladribine to treat multiple sclerosis -- 30. Fingolimod to treat multiple sclerosis -- 31. Dimethyl fumarate to treat multiple sclerosis -- 32. Alemtuzumab to treat multiple sclerosis -- 33. Daclizumab to treat multiple sclerosis -- 34. Laquinimod to treat multiple sclerosis -- 35. Teriflunomide to treat multiple sclerosis -- 36. High-dose methylprednisolone to treat multiple sclerosis -- 37. Use of immunosuppressants to treat multiple sclerosis -- 38. Intravenous immunoglobulin to treat multiple sclerosis -- 39. Plasma exchange treatment for CNS inflammatory demyelinating disease -- 40. Statins in multiple sclerosis -- 41. T-cell-based therapies for multiple sclerosis -- 42. B-cell-based therapies for multiple sclerosis -- 43. Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis -- 44. Hematopoietic stem cell transplantation to treat multiple sclerosis -- 45. Mesenchymal stem cell transplantation to treat multiple sclerosis -- 46. Neuroprotection in multiple sclerosis -- 47. Combination therapy in multiple sclerosis -- 48. Dalfampridine in multiple sclerosis -- 49. Complementary and alternative treatments in multiple sclerosis -- 50. The role of chronic cerebrospinal venous insufficiency in multiple sclerosis -- 51. Disease-modifying therapy for multiple sclerosis in clinical practice -- 52. Treatment for patients with primary progressive multiple sclerosis -- 53. Diagnosis, pathogenesis and treatment of neuromyelitis optica (NMO) spectrum disorders -- 54. Management of pediatric multiple sclerosis -- 55. Use of MRI in the clinical management of multiple sclerosis -- 56. Multiple sclerosis-associated fatigue -- 57. Management of spasticity -- 58. Management of bladder and sexual dysfunction in multiple sclerosis -- 59. Depression in multiple sclerosis -- 60. Assessment and treatment of pain disorders in multiple sclerosis -- 61. Management of medical comorbidities in patients with multiple sclerosis -- 62. Rehabilitation in multiple sclerosis

Résumé : This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors.

Mots-clés : Sclérose en plaques - Traitement / Études cliniques - Méthodologie / Imagerie par résonance magnétique / Sclérose en plaques / Évaluation des résultats (Soins médicaux)

Cote : WL 360 M961 2011